Insider Selling: Medpace (NASDAQ:MEDP) CEO Sells $3,083,825.36 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 5,128 shares of the company’s stock in a transaction that occurred on Thursday, November 13th. The shares were sold at an average price of $601.37, for a total value of $3,083,825.36. Following the completion of the sale, the chief executive officer owned 914,162 shares in the company, valued at $549,749,601.94. The trade was a 0.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Medpace Stock Performance

Medpace stock opened at $590.09 on Monday. The firm has a market cap of $16.62 billion, a price-to-earnings ratio of 41.27, a PEG ratio of 2.67 and a beta of 1.42. Medpace Holdings, Inc. has a 52-week low of $250.05 and a 52-week high of $625.00. The firm has a 50 day moving average price of $539.39 and a two-hundred day moving average price of $424.46.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, beating analysts’ consensus estimates of $3.50 by $0.36. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The company had revenue of $659.90 million for the quarter, compared to analyst estimates of $640.49 million. During the same period in the prior year, the firm posted $3.01 EPS. The company’s quarterly revenue was up 23.7% on a year-over-year basis. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, equities research analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on MEDP. UBS Group cut Medpace from a “neutral” rating to a “sell” rating and raised their target price for the stock from $300.00 to $305.00 in a research note on Tuesday, July 29th. Rothschild & Co Redburn downgraded shares of Medpace from a “buy” rating to a “neutral” rating and raised their price objective for the stock from $342.00 to $474.00 in a research report on Wednesday, September 3rd. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Medpace from $270.00 to $430.00 and gave the company a “hold” rating in a research report on Wednesday, July 23rd. Mizuho increased their target price on shares of Medpace from $575.00 to $655.00 and gave the stock an “outperform” rating in a research note on Friday, October 24th. Finally, Truist Financial set a $555.00 price target on shares of Medpace in a research note on Monday, October 27th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, ten have issued a Hold rating and four have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $487.18.

Institutional Trading of Medpace

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Alps Advisors Inc. raised its holdings in Medpace by 10.0% during the first quarter. Alps Advisors Inc. now owns 1,098 shares of the company’s stock worth $335,000 after buying an additional 100 shares during the last quarter. Signaturefd LLC increased its position in shares of Medpace by 10.8% during the first quarter. Signaturefd LLC now owns 655 shares of the company’s stock worth $200,000 after acquiring an additional 64 shares in the last quarter. Dakota Wealth Management raised its holdings in shares of Medpace by 188.9% in the 1st quarter. Dakota Wealth Management now owns 2,115 shares of the company’s stock worth $644,000 after acquiring an additional 1,383 shares during the last quarter. Whittier Trust Co. raised its holdings in shares of Medpace by 47.3% in the 1st quarter. Whittier Trust Co. now owns 109 shares of the company’s stock worth $33,000 after acquiring an additional 35 shares during the last quarter. Finally, Victory Capital Management Inc. lifted its position in Medpace by 41.7% in the 1st quarter. Victory Capital Management Inc. now owns 23,979 shares of the company’s stock valued at $7,306,000 after acquiring an additional 7,051 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.